0000911421-23-000018.txt : 20230801 0000911421-23-000018.hdr.sgml : 20230801 20230801163123 ACCESSION NUMBER: 0000911421-23-000018 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PARTNERRE LTD CENTRAL INDEX KEY: 0000911421 STANDARD INDUSTRIAL CLASSIFICATION: ACCIDENT & HEALTH INSURANCE [6321] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14536 FILM NUMBER: 231132220 BUSINESS ADDRESS: STREET 1: WELLESLEY HOUSE SOUTH STREET 2: 90 PITTS BAY ROAD CITY: PEMBROKE STATE: D0 ZIP: HM 08 BUSINESS PHONE: 14412920888 MAIL ADDRESS: STREET 1: WELLESLEY HOUSE SOUTH STREET 2: 90 PITTS BAY ROAD CITY: PEMBROKE STATE: D0 ZIP: HM 08 FORMER COMPANY: FORMER CONFORMED NAME: PARTNER RE HOLDINGS LTD DATE OF NAME CHANGE: 19950725 6-K 1 q22023form6-k.htm 6-K Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant To Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of August 2023
Commission File Number 001-14536
PartnerRe Ltd.
(Translation of registrant’s name into English)

Wellesley House South, 90 Pitts Bay Road,
Pembroke HM08, Bermuda
(441) 292-0888
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ý Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).
Yes ¨ No ý
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).
Yes ¨ No ý




DOCUMENTS FURNISHED AS PART OF THIS FORM 6-K

The following documents, furnished as exhibits to this Form 6-K, are incorporated by reference as part of this Form 6-K:
Exhibit  Description of Exhibit
99.1   
Press Release and Supplementary Financial Information – PartnerRe Ltd. first half 2023 results, dated August 1, 2023











SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PartnerRe Ltd.
(Registrant)
Date:
August 1, 2023
By:/s/ Abina Kealy
Name: Abina Kealy
Title: Chief Financial Officer



EXHIBIT INDEX
 
Exhibit  Description of Exhibit
99.1   
Press Release and Supplementary Financial Information – PartnerRe Ltd. first half 2023 results, dated August 1, 2023


EX-99.1 2 q22023ex991-pressrelease.htm EX-99.1 Document
Exhibit 99.1

                                              prelogoa89.jpg
News Release

PartnerRe Ltd. Reports First Half 2023 Results
PEMBROKE, Bermuda, August 1, 2023 - PartnerRe Ltd. ("the Company") today reported first half 2023 results.
Highlights
Net income attributable to common shareholder of $783 million, an improvement of $1,786 million, for an annualized return on equity of 23.9%

Operating income of $636 million for an annualized operating income return on equity of 19.5%, a 4.1% improvement
Net premiums earned grew by 10% reflecting 6% growth in P&C, 7% growth in Specialty and 21% growth in Life and Health
Non-life underwriting result was $466 million, with a combined ratio of 83.5%
Life and health allocated underwriting result of $78 million
Net investment return of $481 million included unrealized gains on fixed maturities and short-term investment of $107 million and an improvement in net investment income of 57%
Cash flows from operating activities of $1,084 million, reflecting growth of 58%
Long Duration Targeted Improvements ("LDTI") accounting standard adopted in Q1 2023; comparable periods have been updated to reflect the adoption
PartnerRe President and Chief Executive Officer Jacques Bonneau commented,
"Favorable market conditions persist half way through 2023, and we remain focused on our disciplined approach to capitalizing on these opportunities and making a meaningful contribution to the Covéa group. Our operating income of $636 million for the first half of 2023 continued its growth trend, up 24% compared to the first half of 2022. The fundamentals across operating segments are strong. For the non-life business we saw an improvement in current underwriting year performance for both the P&C and Specialty segments as compared to the first half of 2022, though the non-life combined ratio increased marginally by 1.6 points, as the first half of 2022 benefited from favorable prior year reserve development. The contribution from the Life and Health business continues to be a positive source of earnings to the group as premium volume grows. Our investment portfolio also performed well, demonstrated by 57% growth in net investment income compared to the first half of 2022, and we expect this trend to continue as we deploy our increasing cash flows from operations at attractive reinvestment rates."
    

Operating income and operating income return on equity are non-GAAP financial measures. See "Non-GAAP Financial Measures - Regulation G" for a reconciliation of non-GAAP measures.
Life and health allocated underwriting result includes net premiums earned, loss and loss expenses, acquisition costs, other income, other expense and allocated net investment income

PartnerRe Ltd.
Wellesley House, 5th Floor
90 Pitts Bay Road
Pembroke, Bermuda HM 08
Telephone +1 441 292 0888
Fax +1 441 292 6080
www.partnerre.com

1

prelogoa89.jpg
PartnerRe Ltd.
Consolidated Statements of Operations and
Comprehensive Income (Loss)
(Expressed in thousands of U.S. dollars)
(Unaudited)  
For the six months ended
June 30, 2023
June 30, 2022 (1)
Revenues
Gross premiums written$5,338,876 $4,976,886 
Net premiums written$4,540,383 $4,253,856 
Increase in unearned premiums(690,012)(748,081)
Net premiums earned3,850,371 3,505,775 
Net investment income285,741 182,571 
Net realized and unrealized investment gains (losses)198,006 (1,725,356)
Other income14,697 18,123 
Total revenues4,348,815 1,981,113 
Expenses
Losses and loss expenses (liability remeasurement loss (gain): 2023, $8,298; 2022, $(87,903))
2,455,919 2,146,598 
Market risk benefit gains(19,649)(109,147)
Acquisition costs788,351 750,881 
Other expenses
216,401 183,498 
Interest expense28,638 27,492 
Amortization of intangible assets3,994 4,502 
Net foreign exchange losses (gains)20,711 (21,103)
Total expenses3,494,365 2,982,721 
Income (loss) before taxes and interest in (loss) earnings of equity method investments854,450 (1,001,608)
Income tax expense(64,110)(13,550)
Interest in (losses) earnings of equity method investments(2,899)16,393 
Net income (loss)787,441 (998,765)
Preferred dividends4,875 4,876 
Net income (loss) attributable to common shareholder$782,566 $(1,003,641)
Comprehensive income (loss)
Net income (loss)$787,441 $(998,765)
Change in currency translation adjustment18,769 (15,593)
Change in net unrealized gains or losses on investments, net of tax(26)— 
Change in unfunded pension obligation, net of tax182 266 
Changes in discount rate for liability for future policy benefits, net of tax12,449 104,723 
Changes in instrument-specific credit risk for market risk benefits, net of tax2,671 44,570 
Comprehensive income (loss)$821,486 $(864,799)
(1) Amounts have been adjusted to reflect the adoption of LDTI.
2

prelogoa89.jpg
PartnerRe Ltd.
Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars, except parenthetical share data)
(Unaudited)   
June 30, 2023
December 31, 2022 (1)
Assets
Investments:
Fixed maturities, at fair value$13,964,101 $13,021,914 
Short-term investments, at fair value837,180 523,510 
Equities, at fair value853,343 929,886 
Investments in real estate60,778 57,984 
Other invested assets3,674,220 3,355,106 
Total investments19,389,622 17,888,400 
Cash and cash equivalents1,086,550 1,251,596 
Accrued investment income120,644 103,752 
Reinsurance balances receivable4,340,327 3,342,612 
Reinsurance recoverable on paid and unpaid losses2,020,401 1,947,786 
Prepaid reinsurance premiums557,784 247,276 
Funds held by reinsured companies459,947 471,570 
Deferred acquisition costs1,095,641 1,012,067 
Market risk benefit assets152,337 131,186 
Deposit assets73,127 81,053 
Net tax assets118,618 177,189 
Goodwill456,380 456,380 
Intangible assets85,821 89,769 
Other assets225,422 203,119 
Total assets$30,182,621 $27,403,755 
Liabilities
Non-life reserves $12,876,953 $12,725,631 
Life and health reserves 2,786,947 2,497,519 
Market risk benefit liabilities4,187 9,170 
Unearned premiums3,753,380 2,745,371 
Other reinsurance balances payable1,056,402 632,336 
Debt1,867,223 1,848,003 
Deposit liabilities4,790 4,681 
Net tax liabilities66,217 55,131 
Accounts payable, accrued expenses and other (2)
652,591 488,593 
Total liabilities23,068,690 21,006,435 
Shareholders’ Equity
Common shares (par value $0.00000001; issued and outstanding: 100,000,000 shares)
 — 
Preferred shares (par value $1.00; issued and outstanding: 8,000,000 shares; aggregate liquidation value: $200,000)8,000 8,000 
Additional paid-in capital1,929,934 1,929,934 
Accumulated other comprehensive income105,356 71,311 
Retained earnings5,070,641 4,388,075 
Total shareholders’ equity7,113,931 6,397,320 
Total liabilities and shareholders’ equity$30,182,621 $27,403,755 
(1) Amounts have been adjusted to reflect the adoption of LDTI.
(2) Includes payables for securities purchased of $268 million as at June 30, 2023 compared to $149 million as at December 31, 2022.

3

prelogoa89.jpg
PartnerRe Ltd.
Non-GAAP Financial Measures - Regulation G
In addition to the GAAP financial measures set forth herein, the Company has also included certain non-GAAP financial measures within the meaning of Regulation G. Management believes that these non-GAAP financial measures are useful to investors and other stakeholders and help provide a consistent basis for comparison between quarters and for comparison with other companies within the industry. These measures may not, however, be comparable to similarly titled measures used by other companies outside of the insurance industry. These non-GAAP measures should be considered an addition to, and not a substitute for, measures of financial performance prepared in accordance with GAAP and investors are cautioned not to place undue reliance on these non-GAAP measures in assessing the Company’s overall financial performance. The reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures in accordance with Regulation G is included within the relevant tables.
Operating Income (Loss) available to Common Shareholder (Operating Income (Loss)); Annualized Operating Return on Average Common Shareholder's Equity (Annualized Operating ROE): The Company uses Operating income (loss) and Annualized Operating ROE to measure performance, as these measures focus on the underlying fundamentals of the Company’s operations. Operating income (loss) is calculated after preferred dividends and excludes the impact of market risk benefit gains (losses), net realized and unrealized gains and losses on investments, net foreign exchange gains and losses, interest in earnings (losses) of equity method investments, favorable or adverse prior years' reserves development for which we have ceded the risk under an adverse development cover (ADC) and related changes in amortization of the deferred gain, the impact of non-recurring transactions such as losses on the redemption of preferred shares, and the cumulative tax effects of these adjustments. The Company calculates Annualized Operating ROE using Operating income (loss) for the period divided by the average common shareholder's equity outstanding for the period. Operating income (loss) should not be viewed as a substitute for Net Income (Loss) prepared in accordance with GAAP. Annualized Operating ROE supplements GAAP information. The Company's management believes that Operating income (loss) is useful to stakeholders because it more accurately reflects the underlying fundamentals of the business by removing the variability arising from activity that is largely independent of its business and underwriting processes, such as: fluctuations in the fair value of market risk benefit assets and liabilities; the fluctuations in the fair value of the Company's investment portfolio; fluctuations in foreign exchange rates; fluctuations of returns on the Company's equity method investments; the impact of retroactive reinsurance agreements where the Company believes adjusting for this development shows the ultimate economic benefit of the ADC; and the impact of non-recurring transactions such as losses on the redemption of preferred shares
 For the six months ended
 June 30, 2023
June 30, 2022 (1)
$
ROE (2)
$
ROE (2)
Net income (loss) attributable to common shareholder$782,566 23.9 %$(1,003,641)(30.3)%
Less: adjustments for non-operating items
Market risk benefit gains19,649 0.6 109,147 3.3 
Net realized and unrealized investment gains (losses)
198,006 6.0 (1,725,356)(52.0)
Net foreign exchange (losses) gains(20,711)(0.6)21,103 0.6 
Interest in (losses) earnings of equity method investments(2,899)(0.1)16,393 0.5 
Adverse prior years' reserve development subject to ADC(61,949)(1.9)(30,571)(0.9)
Tax effects of adjustments14,631 0.4 90,822 2.7 
Operating income$635,839 19.5 %$514,821 15.4 %
 For the six months ended
Calculation of average common shareholder's equityJune 30, 2023
June 30, 2022 (1)
Beginning of period common shareholder's equity$6,197,320 $7,157,428 
End of period common shareholder's equity$6,913,931 $6,109,859 
Average common shareholder's equity$6,555,626 $6,633,644 
As at June 30, 2023
As at December 31, 2022 (1)
Total shareholders' equity$7,113,931 $6,397,320 
Less: Preferred shares, aggregate liquidation value at $25 per share200,000 200,000 
Common shareholder’s equity or book value$6,913,931 $6,197,320 
 
Capital structure:
Total debt $1,867,223 $1,848,003 
Preferred shares, aggregate liquidation value 200,000 200,000 
Common shareholder's equity6,913,931 6,197,320 
Total capital$8,981,154 $8,245,323 
(1) Amounts have been adjusted to reflect the adoption of LDTI.
(2) ROE is calculated as net income or loss attributable to common shareholder divided by average common shareholder's equity, annualized for the period. The average common shareholder's equity is calculated using the sum of the beginning of period and end of period common shareholder's equity divided by two.
4

prelogoa89.jpg















PartnerRe Ltd. is a leading global reinsurer that helps insurance companies reduce their earnings volatility, strengthen their capital and grow their businesses through reinsurance solutions. Risks are underwritten on a worldwide basis through the Company’s three segments: P&C, Specialty, and Life and Health. For the year ended December 31, 2022, total revenues were $5.7 billion. At June 30, 2023, total assets were $30.2 billion, total capital was $9.0 billion and total shareholders’ equity was $7.1 billion. PartnerRe maintains strong financial strength ratings as follows: A.M. Best A+ / Moody’s A1 / Standard & Poor’s A+. 
Please refer to the "Financial Information - Annual Reports" section of the Company's website for a copy of the Company's Annual Report on Form 20-F at: www.partnerre.com/financial-information/annual-reports/. Forward-looking statements contained in this press release, such as those related to company performance, are based on the Company’s assumptions and expectations concerning future events and financial performance and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. PartnerRe’s forward-looking statements could be affected by numerous foreseeable and unforeseeable events and developments such as exposure to catastrophe, pandemic or other large property and casualty losses, credit, interest, currency and other risks associated with the Company’s investment portfolio, adequacy of reserves, levels and pricing of new and renewal business achieved, changes in accounting policies, risks associated with implementing business strategies, and other factors identified in the Company’s reports filed or furnished with the Securities and Exchange Commission. In light of the significant uncertainties inherent in the forward-looking information contained herein, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made. The Company disclaims any obligation to publicly update or revise any forward-looking information or statements. The Company’s estimate for recent catastrophic and pandemic losses is based on a preliminary analysis of the Company’s exposures, the current assumption of total insured industry losses and preliminary information received from certain cedants to date. There is material uncertainty associated with the Company's loss estimates given the nature, magnitude and recency of these loss events and the limited claims information received to date. The ultimate loss therefore may differ materially from the current preliminary estimate.

Contacts: PartnerRe Ltd. (441) 292-0888
Investor Contact: Stephen Boylan
Media Contact: Elizabeth Deacon

partnerre.com
5
GRAPHIC 3 prelogoa89.jpg begin 644 prelogoa89.jpg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